Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, ...

Please provide your email address to receive an email when new articles are posted on . Pembrolizumab plus axitinib continued to exhibit superior efficacy to sunitinib as first-line therapy for ...

BOSTON - An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in ...

A study was conducted to compare cardiovascular outcomes for single-pill antihypertensive combination therapy and identical multiple pill therapy. Risk for CV events and all-cause mortality is ...

Bristol-Myers Squibb Company today announced five-year results from the Phase 3 CheckMate -067 clinical trial, which continues to demonstrate improved overall survival with the first-line combination ...

HOUSTON - A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the ...

Nomogram to predict risk of 30-day mortality for patients with disseminated malignancy undergoing surgical intervention. Background: There is wide variability in the treatment of metastatic breast ...